A new cost-cutting campaign from New York-based Pfizer (NYSE: PFE) demonstrates the intensity of the firm’s focus on ensuring operational efficiencies.
The company has already announced a rationalization and “realignment” program, which is in full swing and on track to deliver around $4 billion in savings by the end of this year.
Pfizer has now said it will engage in a separate, “multi-year program” to reduce the cost of goods sold, targeting operational efficiencies, network structure changes, and product portfolio enhancements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze